Health Care • Biotechnology: Pharmaceutical Preparations
$0.66 ▲ +0.01
(+1.12%)
MKT CAP: $31.8M • VOL: 265.2K
52W L $1 52W H $3
ROARABLE / RQD
D • 47/100
PIOTROSKI
2 / 9
FLNA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$95.4M | -$141.4M | -$106.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$91.0M | -$24.3M | -$97.2M |
| EBITDA (Normalized) | -$94.9M | -$141.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$32.3M | -$116.9M | -$82.0M |
| Capital Expenditures (CapEx) | $581.0K | $103.0K | — |
| Free Cash Flow (FCF) | -$32.8M | -$117.0M | -$82.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $95.5M | $128.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $74.4M | $145.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FLNA.